Company challenges medical community to validate bladder tool
February 15th 2007Verathon, Inc. (Bothell, WA) has issued a challenge to urology researchers: The company is offering $10,000 for the most practical and scientifically valid protocol to study the relationship of bladder wall mass and overactive bladder or BPH. The goal is to determine how bladder wall mass measurements can best be used in clinical practice.
Biomarker test could predict outcome for bladder cancer patients
February 15th 2007A set of molecular biomarkers might predict the recurrence of bladder cancer and survival from the disease better than conventional prognostic features, University of Texas Southwestern Medical Center, Dallas, researchers have found. Once a patient undergoes radical cystectomy, researchers say a routine tissue analysis could easily test for the presence of altered proteins that they found to help ascertain the chances that the cancer will return.
Muscle damage during childbirth is linked to later prolapse
February 15th 2007A new study from the University of Michigan Health System establishes one of the strongest connections yet discovered between muscle damage that can occur during vaginal deliveries and pelvic organ prolapse, the authors say.
FDA approves new labeling for advanced RCC treatment
February 15th 2007The FDA has approved new labeling for sunitinib malate (Sutent) to include first-line treatment of advanced renal cell carcinoma. The labeling change is based on results of a large phase III trial that showed prolonged progression-free survival.
Brachytherapy offers high 8-year prostate Ca survival rates
February 15th 2007More than 90% of men who receive appropriate radiation dose levels with permanent radiation seed implants to treat their prostate cancer are cured of the disease 8 years after diagnosis, according to a recent study in the International Journal for Radiation Oncology Biology Physics (2007; 67:327-33).
Protein marker related to severe form of BPH
February 15th 2007Higher levels of a protein made by a gene known as JM-27 have been found in men whose BPH is more severe and more likely to lead to bladder-related complications if left untreated, according to Johns Hopkins researchers. The team, lead by Robert Getzenberg, PhD, also developed a blood test that detects the JM-27 protein in men with severe symptoms.
Retractile testes should be monitored for ascent
February 1st 2007Atlanta-Secondary testicular ascent (acquired cryptorchidism) remains a relatively rare condition, occurring in 3.2% to 6.9% of patients in a recent cohort study of boys with retractile testes. The diagnosis of ascent is becoming more commonplace, and ,therefore, boys with questionable testicular exams should have follow-up through adolescence, according to re-searchers from the Vanderbilt University Children's Hospital, Nashville, TN.
Obtain your National Provider Identifier number today
February 1st 2007Medicare has mandated a change from the current provider identification system to a new National Provider Identifier (NPI). The change will occur on May 23, 2007. This change is not an option, but is mandated for Medicare and, ultimately, all private payers that accept electronic claims.
Pathogenic E. coli may spread through casual contact
February 1st 2007San Francisco-How uropathogenic Escherichia coli spreads within families is a continuing question for both practicing urologists and researchers. It has long been known that sexual contact may spread specific strains. A new study examining members of a single family confirms that casual contact between family members and even pets can also contribute to the transmission of E. coli, leading to cystitis and possibly other urologic infections.
Resistant E. coli endemic in humans, not animals
February 1st 2007San Francisco-Farm animals often are implicated as the source of drug-resistant Escherichia coli and other pathogens in humans. In some cases, human outbreaks have been traced back to infected farm animals, but a recent study of such outbreaks in Iowa exonerates food herds as the source of resistant E. coli that are responsible for urinary tract infections.
Long-term care: 'Reservoir for quinolone resistance'
February 1st 2007San Francisco-A study at one of the largest health systems in Vancouver, British Columbia, has found that long-term care facilities have become a significant reservoir for resistance to fluoroquinolone antibiotics. The rise of resistance appears to be the result of the increased use of quinolones for empiric treatment of urinary tract infections and pneumonia in residents of these facilities.
Couples share bacterial microflora, study confirms
February 1st 2007San Francisco-A recent study from Sweden has confirmed what many clinicians have suspected: couples routinely share bacterial microflora. In clinical terms, if one partner is treated for a urinary tract infection or similar complaint, the other partner is likely to serve as a reservoir to re-infect the treated person.
Research on bladder tissue regeneration progresses
February 1st 2007Atlanta-Tissue engineering research has grown by leaps and bounds in the past decade and a half, yielding findings that may someday have a profound impact on the field of pediatric urology. At the 2006 American Academy of Pediatrics Section on Urology annual meeting here, several groups presented cutting-edge data on novel systems for organ generation, including research demonstrating the feasibility of generating a functioning bladder from stem cells.
Growing data point to toxins' role in fetal anomalies
February 1st 2007Atlanta-The impact of environmental toxins on male sexual development has become a topic of keen interest among pediatric urologists, who have released a growing body of data suggesting environmental links to hypospadias, cryptorchidism, and other urinary tract anomalies and diseases. At the 2006 American Academy of Pediatrics Section on Urology annual meeting, several groups presented data on the effect of in utero exposure to endocrine disrupters on the developing fetus.
Adult spina bifida patients less sexually active
February 1st 2007Atlanta-Sexual activity is lower and more disturbed in adult patients with spina bifida than it is in the general population, according to a recent study by researchers from the Children's Hospital of Philadelphia. Interestingly, however, this diminished sexual activity does not appear to significantly affect spina bifida patients' quality of life, researchers said at the 2006 American Association of Pediatrics Section on Urology annual meeting here.
Initiatives will support VUR, hydronephrosis research
February 1st 2007Atlanta-A study funded by the National Institutes of Health and a new registry promise to provide needed information on the incidence, prevalence, and consequences of two important urologic conditions in children: vesicoureteral reflux and prenatal hydronephrosis. Both the study and the registry were highlighted at the American Academy of Pediatrics Section on Urology annual meeting here.
Experts debate best approaches to pediatric renal surgery
February 1st 2007Atlanta-For a number of urologic conditions in adult patients, pure laparoscopic and robot-assisted laparoscopic procedures have taken urology by storm. Pediatric urology has been somewhat slower to adopt laparoscopic approaches, but many of the same questions arise in pediatric circles when arguing the relative merits and shortcomings of current laparoscopic and open surgical options: How do postoperative pain scores, operative times, and return to activities compare? What is the learning curve for laparoscopy, and does robotic assistance shorten it? In which patients, and for which indications, is one approach preferred over another?
Pediatric urologists face a challenging future
February 1st 2007Atlanta-Shifting patient and physician demographics, a rapidly changing medical marketplace, and evolving national health policies will create unique challenges for pediatric urology in the next decade, according to William J. Cromie, MD, MBA, a pediatric urologist who is CEO of Capital District Physicians' Health Plan, Inc.
Oral agent shows efficacy as second-line prostate cancer therapy
February 1st 2007New York-Satraplatin, an oral platinum analog in late-stage development as second-line chemotherapy for hormone-refractory prostate cancer, has shown encouraging results in phase III trials, said Oliver Sartor, MD, associate professor of medicine at the Lank Center for Genitourinary Oncology at Dana Farber Cancer Institute, Boston. Dr. Sartor, who reviewed phase III results of the drug at the recent Chemotherapy Foundation Symposium here, said satraplatin is one of the most promising new agents under study for hormone-refractory disease.
Successive therapies may extend survival in AIPC
February 1st 2007New York-The administration of sipuleucel-T (Provenge), an investigational immunotherapy designed to stimulate a patient's immune response, followed by docetaxel chemotherapy prolonged survival in men with asymptomatic androgen-independent prostate cancer (AIPC), according to a recently released study. Median survival in these men was 14 months longer than would have been predicted by a prostate cancer survival nomogram, said Daniel Petrylak, MD, associate professor of medicine and director of genitourinary oncology at Columbia Presbyterian Medical Center in New York.